Flunisolide aerosol for treatment of severe, chronic asthma in steroid-independent children.

doi:10.1542/peds.69.3.340

Paper

Flunisolide aerosol for treatment of severe, chronic asthma in steroid-independent children.

Published Mar 1, 1982 · E. Meltzer, J. Kemp, H. Orgel

Pediatrics

Q1 SJR score

27

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

The efficacy and safety of flunisolide aerosol were studied in 46 steroid-independent children with asthma inadequately controlled by nonsteroid drugs. This was a double-blind, placebo-controlled, parallel study lasting eight weeks. Patients were randomly assigned either flunisolide by inhalation, 0.5 mg twice a day, or placebo. Effectiveness was evaluated daily by symptom scores, by Wright peak flow measurements twice daily, and weekly by spirometry and physical examination. Adrenal function and throat cultures for Candida were evaluated before and after the test-drug treatment period. Flunisolide was administered to 25 patients and 21 received placebo. Most symptom scores were statistically significantly better in flunisolide-treated than in placebo-treated patients; these included severity of wheezing (P = .01), chest tightness (P = .01) and shortness of breath (P = .02), and frequency (P = .001) and severity of asthma attacks (P = .03). In addition, placebo-treated patients used significantly more bronchodilators than flunisolide-treated patients. In the final therapeutic effectiveness evaluation, 72% of flunisolide-treated patients received very good or good ratings, whereas only 29% of placebo-treated patients received these ratings (P = .005). No patient developed thrush, evidence of adrenal suppression, or other severe adverse reaction. Flunisolide aerosol was shown to be effective and safe in controlling asthma in children who were candidates for oral steroid therapy.

RCT

Study Snapshot

Flunisolide aerosol is an effective and safe treatment for severe, chronic asthma in steroid-independent children, improving symptoms and reducing the need for bronchodilators.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Paper

Flunisolide aerosol for treatment of severe, chronic asthma in steroid-independent children.

References

Citations

Airway remodelling in smokers with or without chronic obstructive pulmonary disease (COPD) and the effects of inhaled corticosteroids on remodelling in COPD

Inhaled corticosteroids effectively reverse reticular basement membrane fragmentation in COPD, but do not affect vessel remodelling or angiogenic activities.

Protein- and Lipid Modification of Natural Bovine Surfactant

Sphingomyeline substituted and protein-modified surfactant preparations provide improved and sustained oxygenation compared to SF-Ri1 in a rat model of respiratory failure.

Cost Effectiveness of Inhaled Fluticasone Propionate vs Inhaled Triamcinolone Acetonide in the Treatment of Persistent Asthma

Fluticasone propionate 250g twice daily administered by Diskhaler® is more cost-effective than triamcinolone acetonide 200g four times daily for treating persistent asthma over 24 weeks.

Study designs and challenges in clinical studies conducted in infants and children with asthma.

Budesonide inhalation suspension is an effective asthma medication for infants and young children, allowing for symptom assessment and pulmonary function testing in pediatric patients.

BONE METABOLISM IN CHILDREN WITH ASTHMA TREATED WITH NEBULIZED FLUNISOLIDE: A MULTICENTER ITALIAN STUDY

A 4-month regimen of nebulized flunisolide 1200 g/d is effective in treating mild asthma in children, without altering bone or collagen turnover markers.